Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 13, 2025 | June 16, 2025 |
| LOEWS CORPL · Entity 3231 | Director | March 31, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 13, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2035-06-13 | Direct | 33,350 |
Reported balance
After 2025-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-13 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.
LOEWS CORP
Report date March 31, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,233 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 235 · Balance 5,233 F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 4,159 · Balance 0 F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 2,477 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00. |
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-01 · Disposition to issuer · Disposed 3,363 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.90 · Expires 2023-11-01 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-01 · Disposition to issuer · Disposed 4,045 · Balance 0 F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50. |
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-01 · Disposition to issuer · Disposed 3,252 · Balance 0 F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock. F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F2: This Deferred Stock Unit award, which was granted on November 2, 2020, was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $180,821.00.
F3: This Deferred Stock Unit award, which was granted on November 1, 2019, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $245,499.00.
F4: This option award, which was granted on November 1, 2013, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $125,799.50.
F5: Each Phantom Stock Unit is the economic equivalent of one share of non-voting common stock.
F6: This Phantom Stock Unit award, which was granted on November 1, 2017, was canceled and converted in the Merger into the right to receive a cash payment of $73 per share for a total of $237,396.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Mar 31, 2026 20:25 UTC | LOEWS CORP L · Entity 3231 | GrantCommon Stock | 235 | $0.00 | $0.00 |
DisclosureSEC source: 0001349408-26-000006 · wk-form4_1774988711.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,233 F1 · acquired: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 21:21 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,922 | $110.16 | $211,727.52 |
DisclosureSEC source: 0001349408-26-000004 · wk-form4_1770844879.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,998 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:18 UTC | LOEWS CORP L · Entity 3231 | GrantCommon Stock | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0001349408-26-000002 · wk-form4_1767647882.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,920 F1 · acquired: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:30 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $38.67 | $0.00 |
DisclosureSEC source: 0001349408-25-000008 · wk-form4_1764710998.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:30 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,444 | $108.10 | $156,096.40 |
DisclosureSEC source: 0001349408-25-000008 · wk-form4_1764710998.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,686 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:30 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 806 | $108.13 | $87,152.78 |
DisclosureSEC source: 0001349408-25-000008 · wk-form4_1764710998.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,130 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:30 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $38.67 | $87,007.50 |
DisclosureSEC source: 0001349408-25-000008 · wk-form4_1764710998.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| September 30, 2025 Filed Sep 30, 2025 20:20 UTC | LOEWS CORP L · Entity 3231 | GrantCommon Stock | 251 | $0.00 | $0.00 |
DisclosureSEC source: 0001349408-25-000006 · wk-form4_1759263627.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,686 F1 · acquired: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:19 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001349408-25-000004 · wk-form4_1756930748.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:19 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,422 | $96.67 | $137,464.74 |
DisclosureSEC source: 0001349408-25-000004 · wk-form4_1756930748.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,435 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:19 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 828 | $96.70 | $80,067.60 |
DisclosureSEC source: 0001349408-25-000004 · wk-form4_1756930748.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,857 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:19 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $35.52 | $79,920.00 |
DisclosureSEC source: 0001349408-25-000004 · wk-form4_1756930748.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:19 UTC | LOEWS CORP L · Entity 3231 | GrantCommon Stock | 149 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-25-000152 · wk-form4_1751401175.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,435 F1 · acquired: Represents quarterly grant of common stock in respect of director compensation under the Loews Corporation 2025 Incentive Compensation Plan. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 08:54 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001790340-25-000065 · wk-form4_1750078473.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2035-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:20 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000060086-25-000137 · wk-form4_1748981998.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:20 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,273 | $88.82 | $113,067.86 |
DisclosureSEC source: 0000060086-25-000137 · wk-form4_1748981998.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,286 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:20 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 977 | $88.74 | $86,698.98 |
DisclosureSEC source: 0000060086-25-000137 · wk-form4_1748981998.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,559 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:20 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $38.46 | $86,535.00 |
DisclosureSEC source: 0000060086-25-000137 · wk-form4_1748981998.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| May 14, 2025 Filed May 14, 2025 20:15 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-25-000115 · wk-form4_1747253717.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,288 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 14, 2024, the Reporting Person was granted 1,288 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F3 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 14, 2024, the Reporting Person was granted 1,288 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 14, 2025 Filed May 14, 2025 20:15 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-25-000115 · wk-form4_1747253717.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:18 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0000060086-25-000069 · wk-form4_1741123112.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:18 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,197 | $86.90 | $104,019.30 |
DisclosureSEC source: 0000060086-25-000069 · wk-form4_1741123112.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,998 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:18 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,053 | $86.89 | $91,495.17 |
DisclosureSEC source: 0000060086-25-000069 · wk-form4_1741123112.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,195 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:18 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $40.61 | $91,372.50 |
DisclosureSEC source: 0000060086-25-000069 · wk-form4_1741123112.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 7, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 16:19 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 17,614 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001790340-25-000009 · wk-form4_1735852761.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,614 Underlying: Class A Common Stock · 17,614 shares Expires 2035-01-01 F3 · security: Pursuant to the Compensation Program, the reporting person elected to receive this stock option in lieu of receiving the cash COB Retainer (as defined in the Compensation Program). F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) serving as Chair of the Board (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 16:19 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 23,485 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001790340-25-000009 · wk-form4_1735852761.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,485 Underlying: Class A Common Stock · 23,485 shares Expires 2035-01-01 F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program). F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:22 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $42.52 | $0.00 |
DisclosureSEC source: 0000060086-24-000215 · wk-form4_1733260965.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F3 · price: The Reporting Person received the Derivative Security as a stock appreciation right grant at no cost. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:22 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,146 | $86.48 | $99,106.08 |
DisclosureSEC source: 0000060086-24-000215 · wk-form4_1733260965.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,998 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $86.35 and $86.66. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:22 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,104 | $86.80 | $95,827.20 |
DisclosureSEC source: 0000060086-24-000215 · wk-form4_1733260965.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,144 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:22 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $42.52 | $95,670.00 |
DisclosureSEC source: 0000060086-24-000215 · wk-form4_1733260965.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:22 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $41.98 | $0.00 |
DisclosureSEC source: 0000060086-24-000173 · wk-form4_1725481298.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:22 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 1,087 | $81.38 | $88,460.06 |
DisclosureSEC source: 0000060086-24-000173 · wk-form4_1725481298.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,998 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:22 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,163 | $81.36 | $94,621.68 |
DisclosureSEC source: 0000060086-24-000173 · wk-form4_1725481298.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,085 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:22 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $41.98 | $94,455.00 |
DisclosureSEC source: 0000060086-24-000173 · wk-form4_1725481298.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 16:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-028054 · wk-form4_1718309874.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:18 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.83 | $0.00 |
DisclosureSEC source: 0000060086-24-000136 · wk-form4_1717532322.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:18 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 963 | $75.80 | $72,995.40 |
DisclosureSEC source: 0000060086-24-000136 · wk-form4_1717532322.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,998 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $75.61 and $76.59. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:18 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,287 | $76.59 | $98,571.33 |
DisclosureSEC source: 0000060086-24-000136 · wk-form4_1717532322.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,961 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:18 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.83 | $98,617.50 |
DisclosureSEC source: 0000060086-24-000136 · wk-form4_1717532322.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| May 14, 2024 Filed May 14, 2024 20:24 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000114 · wk-form4_1715718259.xml · derivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,288 Underlying: Common Stock · 1,288 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (each, an "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: These RSUs vest on May 14, 2025. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. F2 · derivative.expiration_date: These RSUs vest on May 14, 2025. Shares of the Issuer's common stock will be delivered to the Reporting Person upon vesting, subject to any election to defer delivery of shares made by the Reporting Person. Read SEC document |
| May 09, 2024 Filed May 9, 2024 12:34 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionRestricted Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000093 · wk-form4_1715258051.xml · derivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 9, 2023, the Reporting Person was granted 1,706 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. F3 · derivative.expiration_date: As previously reported on Table II of a Form 4 filed in connection therewith, on May 9, 2023, the Reporting Person was granted 1,706 RSUs, which vested on the first anniversary of the grant date. The common stock into which such vested RSUs converted is reported on Table I of this Form 4. Read SEC document |
| May 09, 2024 Filed May 9, 2024 12:34 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000060086-24-000093 · wk-form4_1715258051.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · acquired: Represents the conversion into common stock upon vesting of previously awarded restricted stock units ("RSUs"). Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 19:10 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 57,965 | $2.13 | $123,436.47 |
DisclosureSEC source: 0001790340-24-000030 · wk-form4_1710889796.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,465 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.89 to $2.35. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:20 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $43.37 | $0.00 |
DisclosureSEC source: 0000060086-24-000067 · wk-form4_1709586935.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:20 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 951 | $75.02 | $71,344.02 |
DisclosureSEC source: 0000060086-24-000067 · wk-form4_1709586935.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,292 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $75.02 and $75.07. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:20 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,299 | $75.07 | $97,515.93 |
DisclosureSEC source: 0000060086-24-000067 · wk-form4_1709586935.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,243 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:20 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 2,250 | $43.37 | $97,582.50 |
DisclosureSEC source: 0000060086-24-000067 · wk-form4_1709586935.xml · nonDerivative · entry 1 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:16 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 2,250 | $0.00 Strike: $47.84 | $0.00 |
DisclosureSEC source: 0000060086-23-000199 · wk-form4_1701724572.xml · derivative · entry 4 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F3 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:16 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 715 | $70.16 | $50,164.40 |
DisclosureSEC source: 0000060086-23-000199 · wk-form4_1701724572.xml · nonDerivative · entry 3 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,292 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. F2 · price: Represents the weighted average price of multiple transactions with a range of prices between $69.93 and $70.50. The Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 21:16 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,535 | $70.08 | $107,572.80 |
DisclosureSEC source: 0000060086-23-000199 · wk-form4_1701724572.xml · nonDerivative · entry 2 BERMAN ANN E · CIK 0001349408 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,007 F1 · kind: The transactions reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.